Prevencio secures global patents for AI-powered blood test for heart disease

Simple blood draw can detect heart disease: ©Africa Studio - stock.adobe.com

Prevencio Inc., a company specializing in artificial intelligence-powered blood tests for cardiovascular disease, announced it has received patents in the United States, European Union, and Japan for its flagship diagnostic tool, HART CADhs. This marks the second U.S. patent for the novel test, which uses a machine learning algorithm and multiple cardiac protein markers to detect obstructive coronary artery disease (CAD) through a simple blood draw.

The international patent coverage bolsters Prevencio’s intellectual property portfolio and supports the company’s strategy to expand the test's adoption globally. HART CADhs is currently the only AI-based, multi-protein blood test for obstructive CAD on the market.

“Securing patent protection in the U.S., Europe, and Japan marks a major step forward in advancing our innovation and market leadership,” said Rhonda Rhyne, CEO of Prevencio. “These patents reinforce the uniqueness of our HART CADhs test and underscore our commitment to improving cardiovascular diagnostics worldwide.”

Backed by clinical data, FDA Breakthrough Device Designation, and growing provider adoption, the company’s offerings aim to address a significant gap in cardiovascular diagnostics. Prevencio’s second test, HART CVE, predicts a patient’s one-year risk of heart attack, stroke, or cardiovascular death.

James L. Januzzi, cardiologist at Massachusetts General Hospital and Professor at Harvard Medical School, emphasized the importance of the new patents for international accessibility. “Cardiovascular disease is a global problem. International patent protection will help Prevencio to deliver scalable solutions that meet urgent diagnostic needs in the U.S. as well as global markets,” he said.

Cardiovascular disease is the world’s leading cause of death and costs the U.S. health care system over $318 billion annually. Prevencio’s AI-driven tests are designed to reduce these costs through earlier detection and better clinical decision-making.

Advances in AI and biomarker-based cardiovascular diagnostics

The field of cardiovascular diagnostics is rapidly evolving, driven by breakthroughs in artificial intelligence, biomarker science, and non-invasive testing. Prevencio's HART platform is part of a broader movement in cardiology to move beyond traditional stress tests, imaging, and invasive procedures.

AI-powered diagnostics like HART CADhs and HART CVE are making strides by integrating complex protein data with machine learning algorithms to identify patterns invisible to the human eye. This has the potential to detect disease earlier, improve diagnostic precision, and reduce unnecessary procedures.

Other companies are also pushing forward, developing AI-based imaging analyses to identify plaque buildup in arteries from CT scans, or using mobile phone sensors and AI to detect cardiac arrhythmias. Meanwhile, the use of troponin and natriuretic peptides in combination with advanced analytics is enabling earlier identification of heart attacks and heart failure in emergency settings.

The integration of AI with multi-protein panels opens doors for personalized medicine in cardiology. Patients with atypical symptoms, women (who are historically underdiagnosed), and those in remote or underserved communities stand to benefit the most from non-invasive, accurate testing.

As these technologies continue to receive regulatory support and reimbursement backing, experts say AI-driven diagnostics could soon become a standard part of cardiovascular care—improving outcomes while reducing the burden on health care systems.